Celiprolol in angina pectoris.
Celiprolol, a long-acting beta1-selective adrenergic-blocking drug with peripheral beta2-stimulatory and peripheral a2-inhibitory activities, has a unique vasodilator beta-blocker pharmacologic profile. The efficacy and safety of celiprolol in angina pectoris have been demonstrated in multiple studies that highlight its different hemodynamic properties compared with traditional beta-blockers. Celiprolol was found to be an effective antianginal agent compared with placebo. In addition, in angina and ischemia its efficacy was comparable to that of propranolol and atenolol.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy*; D001262:Atenolol / Q000627:therapeutic use; D017272:Celiprolol; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D010919:Placebos; D011412:Propanolamines / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use; D011897:Random Allocation; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D010919:Placebos; D011412:Propanolamines; D014665:Vasodilator Agents; D001262:Atenolol; D011433:Propranolol; D017272:Celiprolol